Therapeutic drug monitoring of mycophenolate mofetil in transplantation.
about
Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patientsA therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT.Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.Evaluation of Mycophenolate Mofetil and Low-Dose Steroid Combined Therapy in Moderately Severe Henoch-Schönlein Purpura Nephritis.Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.Performance of the new mycophenolate assay based on IMPDH enzymatic activity for pharmacokinetic investigations and setup of Bayesian estimators in different populations of allograft recipients.Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantationPharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation.Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation.A limited sampling strategy for estimation of the area under the curve (0 to 8 hours) of mycophenolic acid administered three times daily to liver transplant recipientsMycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection.Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part IUGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients.Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation.New-onset diabetes after renal transplantation: risk assessment and management.A comprehensive review of the published assays for the quantitation of the immunosuppressant drug mycophenolic acid and its glucuronidated metabolites in biological fluids.Time-dependent clearance of mycophenolic acid in renal transplant recipientsEffects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients.Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients.UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipientsMonitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesTherapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.Safety considerations with mycophenolate sodium.A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN): an open-label, randomised controlled trialPharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation.Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes.Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium.State of the art in therapeutic drug monitoring.Pharmacogenetic influences on mycophenolate therapy.LC-MS/MS for immunosuppressant therapeutic drug monitoring.The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune diseaseClinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.Genes and beans: pharmacogenomics of renal transplant.How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?Acute mycophenolate overdose: case series and systematic literature analysis.Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients.
P2860
Q28272907-09A7BDB0-F131-4151-AAAE-E0664FCC6225Q33551422-E9A0CBC4-BF83-4D3D-9F49-A55E483C13EAQ33684048-AE2F231F-02F4-40A2-B128-1B56AB4E9B7AQ33696568-68819CA5-588F-4936-8B9C-35FC20F91C69Q33728060-099B7B3A-FA6C-4D47-940A-9DE6A38584E3Q33764989-4C32DECF-BD0C-48ED-B449-6AB2E1460BD0Q33764995-903668DB-7686-472C-BB5F-D488579E9830Q34077882-27E06A54-4D99-4AF4-A1C3-61165975C6DBQ34180482-9B028947-21B2-4CE5-B084-F5E2DA119570Q34287623-9A4F3CB0-A1B9-4B4C-8987-6B9B0B24382CQ34339626-1F462B3C-CDFB-42BC-B277-640C1B4D2492Q34577357-4858D7D0-307D-4F1F-AEEA-DA96B431923AQ34607590-B9398A28-4E30-4A75-A542-84A2A378FB65Q34610933-F4D073FE-8F4B-451F-98A2-55DC0C81277CQ34947658-ABF85F1C-C0AE-46E5-BD45-A045DDBDE57EQ35486258-327BECC4-5FBD-473A-A42D-30070EEAB070Q35620221-F636BD6D-EDDE-4EE1-8807-B9A3B6743032Q35893989-E32F4F4D-0255-47EE-9A38-4104CC360B9CQ36024478-C21A88C2-3215-4465-80B0-C132BA04028BQ36025085-88A67236-ACB7-4534-BCA9-93F800E50071Q36379888-3F85481C-7D30-4807-BEBD-16713542F181Q36400272-8546AD49-AD9E-4FF9-848C-08553C038B2DQ36724093-AD4DA0AB-5BFC-47D6-8508-BF24E22F7812Q36788423-3524BA6A-61DF-43F4-A9A4-3515770E8210Q36792638-239301A6-E2F3-4AF4-8D83-55B64F66398BQ36905861-FB68FA6B-7E91-42C5-A9EA-53EED8CAD05FQ37086991-45B2DCB2-86EB-47CB-848E-244BA35985ABQ37112472-70FA2383-4B4B-45C5-AF60-16A0567B019EQ37438051-4CD76249-55F9-4918-9389-B42E8D4416ABQ37441778-7BCB4AB9-4106-4451-96BC-9C2E780061A5Q37582505-51432BD7-4FB4-4B01-B2A2-10D8ECCA4A47Q37699413-EE7EB4AE-439D-4F91-B2FD-DF9B3317351DQ37710509-A5F35713-5AA4-4DF0-9C96-A57412CB9E15Q37810219-CDF25A2E-0E61-4054-A1C3-849EC78E6942Q37818144-D4493330-B23E-4BBF-8EDC-87B0AB65F68EQ38087925-4671D569-24DF-4508-9BD9-D33AD42A8C22Q38104742-83425E29-EB96-4EDA-857E-7D23A840B921Q38170321-3B04D04D-9F62-4F96-B3A1-9F03A877DB2DQ38198150-2F81AB58-891E-433D-B04A-18406050C70AQ38817096-4656A9E9-86DC-407D-9423-4158C37D61BC
P2860
Therapeutic drug monitoring of mycophenolate mofetil in transplantation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Therapeutic drug monitoring of mycophenolate mofetil in transplantation.
@ast
Therapeutic drug monitoring of mycophenolate mofetil in transplantation.
@en
type
label
Therapeutic drug monitoring of mycophenolate mofetil in transplantation.
@ast
Therapeutic drug monitoring of mycophenolate mofetil in transplantation.
@en
prefLabel
Therapeutic drug monitoring of mycophenolate mofetil in transplantation.
@ast
Therapeutic drug monitoring of mycophenolate mofetil in transplantation.
@en
P2093
P1476
Therapeutic drug monitoring of mycophenolate mofetil in transplantation.
@en
P2093
Bruce Kaplan
Bruno Meiser
Burkhard Toenshoff
Curtis Holt
David DeNofrio
David W Holt
Dirk Kuypers
Leslie M Shaw
Michael Oellerich
Richard D Mamelok
P304
P356
10.1097/01.FTD.0000199358.80013.BD
P577
2006-04-01T00:00:00Z